Effects of antenatal breast milk expression on maternal and infant outcomes: a systematic review and meta-analysis Authors: Zhongyan Cao, Meiling Huang, Ying Liu, Jinzhu Yin, Xinyan Zhao Published: 2026 ABSTRACT BackgroundAntenatal breast milk expression (ABME) is a potential strategy to promote breastfeeding, but its clinical safety and efficacy remain unclear.ObjectiveThe study aims to systematically evaluate the impact of ABME on breastfeeding, maternal, and neonatal outcomes.MethodsEleven electronic databases were searched from inception to January 14, 2026, to identify randomized controlled trials (RCTs) investigating ABME. Study quality was assessed using the Cochrane Risk of Bias tool. Heterogeneity was evaluated using the I2 statistic and χ2 test. Meta-analyses were performed using random-effects models in Review Manager (RevMan version 5.4). The primary outcome was the rate of delayed onset of lactogenesis II (DOL II), defined as copious milk secretion occurring beyond 72 h postpartum.ResultsA total of 3,077 studies were identified. After the removal of duplicates and selection, eleven RCTs studies involving 1,571 women met the inclusion criteria and eight studies were included in the meta-analysis. Compared to the standard care group, women who performed ABME have a lower risk of DOL II in the postpartum period (odds ratio [OR]: 0.30; 95% CI: 0.16–0.56; I2 = 24%, Z = 3.71, P<0.01;Number Needed to Treat (NNT) = 8). Furthermore, mothers in the ABME group were significantly more likely to achieve exclusive breastfeeding within the first 24 h postpartum (OR: 4.68; 95% CI: 2.43–9.02; P < 0.01; NNT = 4 ). ABME also positively affected exclusive breastfeeding at 1–2 (odds ratio [OR]: 2.59; 95% CI: 1.39–4.8, I2 = 0%, Z = 3.01, P = 0.003) and 3–4 weeks postpartum (odds ratio [OR]: 2.53; 95% CI: 1.24–5.15, I2 = 29%, Z = 2.55, P = 0.01). Additionally, no significant differences were found between the ABME and standard care group in maternal or infant outcomes.ConclusionABME effectively reduces the incidence of DOL II and supports early exclusive breastfeeding without compromising maternal or neonatal safety.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12884-026-09299-4. Background The World Health Organization and the United Nations Children’s Fund recommend exclusive breastfeeding for the first six months postpartum, continuing until the child is two years of age or older [1]. The initiation of lactogenesis II is crucial for successful breastfeeding among postpartum women [2]. Clinical practice guidelines advocate for breastfeeding to commence as soon as possible after birth due to its well-documented benefits for both infant and maternal health [3–5]. Typically, most women experience copious milk secretion 2–3 days after giving birth (Lactogenesis II), with the sensation of breast fullness marking the initiation of lactation. However, failure to initiate lactation within 72 h is defined as delayed onset of lactogenesis II (DOL II) [6], which can negatively impact breastfeeding success [2, 7]. While DOL II is a common concern for all primiparous women, its clinical implications are particularly acute in high-risk populations. For instance, gestational diabetes has been shown to be associated with delays or interruptions in this lactation stage [8, 9], and infants born to these mothers face an increased risk of hypoglycemia [10, 11], often requiring supplemental feeding [12]. To address these challenges, ABME may serve as a viable intervention, allowing for colostrum collection and storage prior to birth. This practice can prevent the need for breastmilk substitutes (such as infant formula) and enhance blood glucose stabilization in newborns at risk of hypoglycemia [13]; thus, ABME could facilitate improved outcomes for both mothers and infants by supporting breastfeeding initiation and continuation. Although ABME has demonstrated potential benefits, such as accelerating the onset of lactogenesis II [14] and reducing supplemental formula use during hospitalization [15], there is still concern that ABME can induce preterm labor or miscarriage because its stimulation of oxytocin secretion [16]. Indeed, a retrospective cohort [17] observed that infants of mothers who performed ABME were more likely to be admitted to special care baby units.While pioneering trials, such as the RCT by Foster et al. [18], have focused on the safety of ABME in diabetic mothers, a recent systematic review by Sobik et al. [19] noted that high-quality evidence remains fragmented and sparse, particularly for these high-risk subgroups. This highlights a significant gap between growing clinical interest and the availability of robust, synthesized data necessary to guide practice for both low-risk and high-risk pregnancies. Despite the widespread adoption of ABME in breastfeeding and maternity support programs, existing evidence on its safety and efficacy is primarily derived from small observational studies with notable methodological limitations. Consequently, there is a need for a comprehensive synthesis of the literature to guide clinical decision-making. Accordingly, we aimed to incorporate multiple randomized controlled trials (RCTs) to provide a summarized evaluation of maternal and neonatal outcomes associated with ABME, aiming to clarify its overall clinical impact while identifying areas where evidence remains insufficient. Methods The protocol for this systematic review was developed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) protocol [20]. This systematic review was prospectively registered with PROSPERO International Prospective Register of Systematic Reviews (PROSPERO identifier CRD42024603461). All data came from published articles; thus, ethical approval was not required for this study. Study selection criteria Inclusion criteria We included studies investigating the effects of ABME and DOL II or breastfeeding and limited the studies to randomized controlled trial study designs published in all languages.P: Pregnant womenI: ABMEC: Routine care and related lactation educationO: Incidence of DOL II, breastfeeding outcomes, maternal outcomes and infant outcomes P: Pregnant women P: Pregnant women I: ABME I: ABME C: Routine care and related lactation education C: Routine care and related lactation education O: Incidence of DOL II, breastfeeding outcomes, maternal outcomes and infant outcomes O: Incidence of DOL II, breastfeeding outcomes, maternal outcomes and infant outcomes Exclusion criteria Studies with inaccessible or non-convertible full texts and dataReview, abstract, and conference papersRepeated publicationsLiterature with a low-quality evaluation Studies with inaccessible or non-convertible full texts and data Studies with inaccessible or non-convertible full texts and data Review, abstract, and conference papers Review, abstract, and conference papers Repeated publications Repeated publications Literature with a low-quality evaluation Literature with a low-quality evaluation Search strategy To locate papers that fit the eligibility criteria, eleven electronic databases were thoroughly searched: PubMed, Embase, Cochrane Library, Web of Science, Scopus, Ovid, Wangfang Data, China National Knowledge Infrastructure Database (CNKI), Chinese Scientific Journal Database (VIP), Chinese Biomedical Database (CBM), and EBSCOhost. To ensure the completeness of the search, we also searched clinical registration centers and grey databases: WHO ICTRP: World Health Organization International Clinical Trials Registry Platform, CENTRAL: Cochrane Central Register, ClinicalTrials.gov: United States National Library of Medicine ClinicalTrials.gov, Opengery. Free and MESH terms were combined to create the retrieval approach, which was then modified for use with various databases and clinical registration centers. Those words were as follows: (((breast milk expression AND ((antenatal* OR before birth* OR prenatal) OR (breastmilk* OR breast milk* OR colostrum OR (milk express*)))) AND (Pregnancy OR pregnant women OR pregnan* OR gestational* OR maternal* OR maternity*). All the databases were searched from inception to Oct 1st, 2024, and no language restrictions exist. The literature search was subsequently updated on January 14th, 2026, to ensure the inclusion of the most recent studies. Study selection We used the Endnote20 to organize and de-duplicate the literature that was retrieved. Additionally, we manually checked for duplicates to ensure none were overlooked. Titles and abstracts were initially screened by two experienced reviewers (Cao and Liu). After a full-text review, eligible studies were selected and assessed for quality. The two reviewers worked independently, with no communication between them prior to reviewing the screening results. Discrepancies were solved through discussion, and articles were included based on mutual consensus. Definitions Delayed onset of lactogenesis II (DOL II) is operationally defined as the copious milk secretion that occurs beyond 72 h postpartum. This phenomenon is typically assessed through maternal self-report of subjective symptoms, including breast firmness, fullness, or spontaneous leakage of breast milk [6]. These indicators serve as proxies for assessing the timing and adequacy of lactogenesis II in both clinical and research contexts. Infant Feeding Status includes three categories: exclusive breastfeeding, any breastfeeding, and formula feeding. Exclusive breastfeeding refers to the practice of feeding an infant only breast milk after birth, without providing any other food or beverage, including water. However, vitamins, mineral supplements, and medicinal drops or syrups may be administered [21]. Quality assessment The quality of eligible studies was appraised using the Cochrane Collaboration Risk of Bias Tool (RoBT) [22] which is a methodical procedure that allows studies to be evaluated in relation to predetermined standards. Each study was rated high, low, or unclear in the following domains: selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias. The RoBT was completed independently by two reviewers (Cao and Liu). If there were disagreements, consensus was reached through discussion with two other reviewers (Yin and Zhao). If there were insufficient details to confidently assess methodological quality, the study authors were contacted; if no response was received after three attempts, the quality of the study was assessed based on the available information. Data extraction Data were independently extracted from eligible studies by three reviewers (Cao, Yin, and Liu). The following information was collected: first author’s name, year of publication, study design, participant characteristics, sample size, intervention details (including start time, frequency, total duration, and method ), comparison details, and outcome measures. In cases of duplicate data, only the data from the study with the larger sample size were retained. If the data were missing or unclear, the other reviewer (Huang) contacted the study authors via e-mail with a maximum of three attempts. Outcome The primary outcome was the rate of DOL II. The secondary outcomes were as follows: Breastmilk feeding exclusively for first 24 hInfant feeding status in hospitalInfant feeding status at 1–2 weeks postpartumInfant feeding status at 3–4 weeks postpartumInfant feeding status at 3 months postpartumSpontaneous vaginalCesarean sectionBlood lossNICU admissionApgar score at 5 min Breastmilk feeding exclusively for first 24 h Breastmilk feeding exclusively for first 24 h Infant feeding status in hospital Infant feeding status in hospital Infant feeding status at 1–2 weeks postpartum Infant feeding status at 1–2 weeks postpartum Infant feeding status at 3–4 weeks postpartum Infant feeding status at 3–4 weeks postpartum Infant feeding status at 3 months postpartum Infant feeding status at 3 months postpartum Spontaneous vaginal Spontaneous vaginal Cesarean section Cesarean section Blood loss Blood loss NICU admission NICU admission Apgar score at 5 min Apgar score at 5 min Data analysis The effects of ABME on maternal and infant outcomes were reported in each study. Pooled odds ratios (OR) with 95% confidence intervals (CI) were used to summarize the meta-analysis results. Most outcomes were binary variables, represented by OR and 95% CI. For continuous variables, the mean difference (MD) was used when data were analyzed with the same measurement tool. If different tools were used, the Standardized Mean Difference (SMD) and 95% CI were calculated. Additionally, the effects of ABME on breastfeeding outcomes were assessed using the random effects model, due to anticipated heterogeneity across study population, time, race, and prenatal care studies. Heterogeneity was assessed using the I2 statistic [23]. I2 statistics ranging from 0 to 40% were classified as ‘not important’, those from 30 to 60% may represent ‘moderate heterogeneity’, 50% to 90% may represent ‘substantial heterogeneity’, and values from 75 to 100% as ‘considerable heterogeneity’ [23, 24]. For substantial heterogeneity (I2> 50%), a sensitivity analysis was planned using a case-by-case elimination method. All analyses were two-tailed, and results were considered significant if the P value was less than 0.05. The meta-analysis was performed by using Review Manager (RevMan) software version 5.4 provided by Cochrane Collaboration Network [25]. Given the inherent physiological differences and intervention effects between pregnant women with gestational diabetes mellitus (GDM) and healthy pregnant women, this study divides the included literature into two separate cohorts for distinct analysis. For the eight studies involving healthy pregnant women, a meta-analysis was conducted using RevMan 5.4 software. In contrast, four studies involved pregnant women with gestational diabetes mellitus (GDM). Three of these studies were derived from the same clinical trial (registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000217909) and reported different outcome measures, due to the limited number of studies and the clinical heterogeneity, a quantitative synthesis was not performed. Instead, a descriptive summary was provided. Results Study selection A total of 3,077 studies were identified through the search process. After removing duplicates, 2649 titles and abstracts were screened for further examination. The most common reason for exclusion at this stage was that the study content did not align with our research design. Eighty-nine studies were selected for full-text review, and eleven studies involving 1,571 women met our eligibility criteria and were included in the systematic review. The detailed screening process is shown in Fig. 1 (PRISMA Flow Diagram Fig. 1). Among these particpants, 761 pregnant women underwent ABME before delivery. Most women were in the low-risk singleton category, though some with gestational diabetes mellitus. Fig. 1PRISMA Flow Diagram PRISMA Flow Diagram Study characteristics Of the 11 included studies, eight studies recruited healthy women with low-risk pregnancies (see Table 1 for detailed characteristics), whereas three studies focused on women with gestational diabetes mellitus (GDM) or pre-existing diabetes during pregnancy, with study characteristics presented in Table 2. These studies were conducted in various countries: two [26, 27] in the USA, three [28–30] in China, two [31, 32] in India, one [33] in Denmark, and three [18, 34, 35] in Australia. Sample size ranged from 36 to 632 women. In seven studies [26–32], ABME was initiated at 37 weeks of gestation, in three studies [18, 34, 35], the intervention commenced at 36 weeks, and in one study [33], initiation occurred at 34 weeks of gestation. Table 1Characteristics of studies involving low-risk singleton pregnancies (N = 8)Authors/YearsCountryParticipant characteristicsSize(I/C)Intervention (Antenatal breast milk expression)ComparisonOutcomesStart timeFrequencyMethodMilking durationChen 2021 [29] ChinaAge less than 35 years old; 37 weeks of pregnancy; natural pregnancy; nulliparous women; normal prenatal examination results; normal breast and nipple development; willingness to breastfeed; able to communicate normally.75(39/36)37 weeks of gestation3 times per dayHandexpress10 minStandard care(1) The breastfeeding self-efficacy(2) Lactation initiation time(3) Exclusive breastfeeding rateDemirci 2022 [26]USALow-risk, nulliparous women; individuals at 34–36 weeks.36(18/18)37 weeks of gestation1–2 times per dayHand express10 minEducation(1) Infant gestational age at birth(2) Neonatal intensive care unit admissions(3) Delayed onset of lactogenesis II(4) The use of infant formula(5) Breastfeeding self-efficacyEstafanous 2023 [27] USANulliparous and multiparous women who had not exclusively breastfed their prior infants for 6 or more months.185 (66/119)37 weeks of gestation3 times per dayWith a dual electric breast pump20 min per sessionStandard education on lactation and lactational support at the hospital.(1) Formula use during the hospital stay(2) Exclusive breastfeeding at 6 months(3) Peripartum safety outcomesGuo 2023 [28]ChinaAge: 18–34 years old, nulliparous women, gestational age: 37 weeks; singleton pregnancy; willing to breastfeed; Able to communicate normally and express language fluently, without reading difficulties.128(63/65)37 weeks of gestationTwice per dayHandexpress10 minRoutine prenatal and postpartum care(1) Lactation initiation time(2) Exclusive breastfeeding rate(3) Antenatal breast milk expression awareness rateGeng 2024 [30]China36–37 weeks of pregnancy; nulliparous women; no abnormalities in prenatal examination results; normal breast and nipple structure; willing to breastfeed.80(40/40)37 weeks of gestation3 times per dayHandexpress10 minroutine breastfeeding health education(1) The breastfeeding self-efficacy(2) Lactation initiation time(3) Exclusive breastfeeding rateLamba 2016 [31]India37 weeks of gestation with no obstetrical and medical risk factors; nulliparous and multiparous women.200(100/100)37 weeks of gestationAt least 1 time per dayHandexpress5 minStandard care(1) lactational intervals(2) Infant post-feed weight gainSingh 2009 [32]IndiaNulliparous and multiparous women; term pregnancy.180(90/90)37 weeks of gestationAt least 1 time per dayHand express5 minStandard care(1) lactational intervalsSimonsen 2025 [33]DenmarkHealthy;≥ 18-year-old nulliparous women with a singleton pregnancy; planning to exclusively breastfeed; and had a pre-pregnancy BMI ≤ 27 kg/m2.55(28/27)34 weeks of gestationTwice per dayHand express5 min at each breastStandard care(1) Gestational age at birth(2) The availability of antenatal milk assessed by mL of milk per week, if any, and the total number of expressions per week(3) Infants fed exclusively with MOM the first 24 h postpartum, and breastfeeding rates evaluated at 1, 2, 4, 6, and 8 weeks after birth Table 1Characteristics of studies involving low-risk singleton pregnancies (N = 8)Authors/YearsCountryParticipant characteristicsSize(I/C)Intervention (Antenatal breast milk expression)ComparisonOutcomesStart timeFrequencyMethodMilking durationChen 2021 [29] ChinaAge less than 35 years old; 37 weeks of pregnancy; natural pregnancy; nulliparous women; normal prenatal examination results; normal breast and nipple development; willingness to breastfeed; able to communicate normally.75(39/36)37 weeks of gestation3 times per dayHandexpress10 minStandard care(1) The breastfeeding self-efficacy(2) Lactation initiation time(3) Exclusive breastfeeding rateDemirci 2022 [26]USALow-risk, nulliparous women; individuals at 34–36 weeks.36(18/18)37 weeks of gestation1–2 times per dayHand express10 minEducation(1) Infant gestational age at birth(2) Neonatal intensive care unit admissions(3) Delayed onset of lactogenesis II(4) The use of infant formula(5) Breastfeeding self-efficacyEstafanous 2023 [27] USANulliparous and multiparous women who had not exclusively breastfed their prior infants for 6 or more months.185 (66/119)37 weeks of gestation3 times per dayWith a dual electric breast pump20 min per sessionStandard education on lactation and lactational support at the hospital.(1) Formula use during the hospital stay(2) Exclusive breastfeeding at 6 months(3) Peripartum safety outcomesGuo 2023 [28]ChinaAge: 18–34 years old, nulliparous women, gestational age: 37 weeks; singleton pregnancy; willing to breastfeed; Able to communicate normally and express language fluently, without reading difficulties.128(63/65)37 weeks of gestationTwice per dayHandexpress10 minRoutine prenatal and postpartum care(1) Lactation initiation time(2) Exclusive breastfeeding rate(3) Antenatal breast milk expression awareness rateGeng 2024 [30]China36–37 weeks of pregnancy; nulliparous women; no abnormalities in prenatal examination results; normal breast and nipple structure; willing to breastfeed.80(40/40)37 weeks of gestation3 times per dayHandexpress10 minroutine breastfeeding health education(1) The breastfeeding self-efficacy(2) Lactation initiation time(3) Exclusive breastfeeding rateLamba 2016 [31]India37 weeks of gestation with no obstetrical and medical risk factors; nulliparous and multiparous women.200(100/100)37 weeks of gestationAt least 1 time per dayHandexpress5 minStandard care(1) lactational intervals(2) Infant post-feed weight gainSingh 2009 [32]IndiaNulliparous and multiparous women; term pregnancy.180(90/90)37 weeks of gestationAt least 1 time per dayHand express5 minStandard care(1) lactational intervalsSimonsen 2025 [33]DenmarkHealthy;≥ 18-year-old nulliparous women with a singleton pregnancy; planning to exclusively breastfeed; and had a pre-pregnancy BMI ≤ 27 kg/m2.55(28/27)34 weeks of gestationTwice per dayHand express5 min at each breastStandard care(1) Gestational age at birth(2) The availability of antenatal milk assessed by mL of milk per week, if any, and the total number of expressions per week(3) Infants fed exclusively with MOM the first 24 h postpartum, and breastfeeding rates evaluated at 1, 2, 4, 6, and 8 weeks after birth Characteristics of studies involving low-risk singleton pregnancies (N = 8) Hand express (1) The breastfeeding self-efficacy (2) Lactation initiation time (3) Exclusive breastfeeding rate (1) Infant gestational age at birth (2) Neonatal intensive care unit admissions (3) Delayed onset of lactogenesis II (4) The use of infant formula (5) Breastfeeding self-efficacy (1) Formula use during the hospital stay (2) Exclusive breastfeeding at 6 months (3) Peripartum safety outcomes Hand express (1) Lactation initiation time (2) Exclusive breastfeeding rate (3) Antenatal breast milk expression awareness rate Hand express (1) The breastfeeding self-efficacy (2) Lactation initiation time (3) Exclusive breastfeeding rate Hand express (1) lactational intervals (2) Infant post-feed weight gain (1) Gestational age at birth (2) The availability of antenatal milk assessed by mL of milk per week, if any, and the total number of expressions per week (3) Infants fed exclusively with MOM the first 24 h postpartum, and breastfeeding rates evaluated at 1, 2, 4, 6, and 8 weeks after birth Table 2Characteristics of studies involving pregnancies complicated by diabetes (N = 3)Authors/YearsCountryParticipant characteristicsSize(I/C)Intervention (Antenatal breast milk expression)ComparisonOutcomesStart timeFrequencyMethodMilking durationForster 2017 [18]AustraliaPre-existing or gestational diabetes in a singleton pregnancy from 34 to 37 weeks’ gestation.632(317/315)36 weeks of gestationTwice per dayHandexpress10 minStandard care(usual midwifery and obstetric care, supplemented by support from a diabetes educator)(1) The proportion of infants admitted to the NICU(2) Gestational age at birth(3) The proportion of infants receiving breastmilk exclusively during the initial hospital staysMoorhead 2024 [34]AustraliaPreexisting (Type I or Type II) or gestational diabetes but were otherwise considered at low risk of complications, with a singleton preg-nancy, planning to breastfeed, and proficient in English.566(282/284)36 weeks of gestationTwice per dayHandexpress10 minStandard care(1) Breastfeeding outcomes at 3 monthsMoorhead 2025 [35]AustraliaLow-risk women with diabetes in pregnancy; a singleton pregnancy; cephalic presentation; planning to breastfeed.509(265/244)36 weeks of gestationTwice per dayHandexpress10 minStandard care(1) onset of Lactogenesis II Table 2Characteristics of studies involving pregnancies complicated by diabetes (N = 3)Authors/YearsCountryParticipant characteristicsSize(I/C)Intervention (Antenatal breast milk expression)ComparisonOutcomesStart timeFrequencyMethodMilking durationForster 2017 [18]AustraliaPre-existing or gestational diabetes in a singleton pregnancy from 34 to 37 weeks’ gestation.632(317/315)36 weeks of gestationTwice per dayHandexpress10 minStandard care(usual midwifery and obstetric care, supplemented by support from a diabetes educator)(1) The proportion of infants admitted to the NICU(2) Gestational age at birth(3) The proportion of infants receiving breastmilk exclusively during the initial hospital staysMoorhead 2024 [34]AustraliaPreexisting (Type I or Type II) or gestational diabetes but were otherwise considered at low risk of complications, with a singleton preg-nancy, planning to breastfeed, and proficient in English.566(282/284)36 weeks of gestationTwice per dayHandexpress10 minStandard care(1) Breastfeeding outcomes at 3 monthsMoorhead 2025 [35]AustraliaLow-risk women with diabetes in pregnancy; a singleton pregnancy; cephalic presentation; planning to breastfeed.509(265/244)36 weeks of gestationTwice per dayHandexpress10 minStandard care(1) onset of Lactogenesis II Characteristics of studies involving pregnancies complicated by diabetes (N = 3) Hand express (1) The proportion of infants admitted to the NICU (2) Gestational age at birth (3) The proportion of infants receiving breastmilk exclusively during the initial hospital stays Hand express Hand express Most studies used hand expression, with only one study [27] employing a dual electric breast pump. The frequency of milk expression ranged from at least once to a maximum of three times per day, with session durations not exceeding 20 min. Follow-up periods ranged from one to twelve weeks. It is worth noting that among these eleven studies, three studies [18, 34, 35] had data from the same population, but reported different outcomes. Risk of bias assessment The seven studies had a low risk of bias regarding random sequence generation and allocation concealment. Due to the nature of ABME interventions, which were conducted in the presence of pregnant participants, blinding was not feasible. Consequently, eleven studies had limited blinding of participants, personnel, and outcomes, resulting in a high risk of bias. Most studies reported results comprehensively, and as the majority indicated no significant effects, the risk of bias for selective reporting was considered low. The quality of the included RCTs ranged from low to moderate, as assessed by the Cochrane Risk of Bias 2.0 tool. A summary of the risk of bias assessment for the included RCTs is provided in supplementary figure S1 and S2. Effects of ABME in women with low-risk pregnancies Breastfeeding outcomes Delayed onset of lactogenesis Ⅱ Six studies [26, 28–32] reported DOL Ⅱ, with some [26, 28, 29, 31] using maternal perception to determine the onset of lactogenesis, while two studies [30, 32] did not specify the method. We conducted a meta-analysis, which indicated that pregnant women who practiced ABME had a significantly lower risk of DOL II in the postpartum period compared to those who did not perform milk expression before delivery (odds ratio [OR]: 0.3; 95% CI: 0.16–0.56; I2 = 24%, Z = 3.71, P<0.01) (Fig. 2). Based on the pooled control event rate (CER) of 19.5%, the absolute risk reduction (ARR) was calculated to be 12.7%. This corresponds to an NNT of 8 (95% CI: 6–13), suggesting that for every eight women who perform antenatal breast milk expression, one additional case of delayed lactation is prevented. Fig. 2 Forest plot of delayed onset of lactogenesis Forest plot of delayed onset of lactogenesis Breastmilk feeding exclusively for first 24 h There are three studies [28–30] that examine the outcome of exclusive infant feeding at first 24 h. We conducted a meta-analysis of the data from these studies [28–30] and the results indicated that the rate of exclusive breastfeeding within 24 h was significantly higher among mothers who expressed milk antenatally (odds ratio [OR]: 4.68; 95% CI: 2.43–9.02; I2 = 0%, Z = 4.61, P<0.01) (Fig. 3). With a pooled control event rate of 12.1%, the absolute risk reduction was 27.0%, resulting in an NNT of 4 (95% CI: 2–8). This suggests that ABME is a highly effective intervention for promoting early breastfeeding exclusivity. Fig. 3Forest plot of breastmilk feeding exclusively for first 24 hours Forest plot of breastmilk feeding exclusively for first 24 hours Infant feeding status in hospital Two studies [26, 27] assessed the use of infant formula in hospitals. Our meta-analysis revealed that the use of formula during hospitalization was not statistically significantly associated with ABME (odds ratio [OR]: 0.83; 95% CI: 0.37–1.85, I2 = 30%, Z = 0.46, P = 0.65) (Fig. 4) Similarly, two studies [26, 27] assessed the use of expressed breast milk feeding in hospitals. Our meta-analysis showed that the use of expressed breast milk during hospitalization was not significantly associated with ABME (odds ratio [OR]: 2.02; 95% CI: 0.22–18.18, I2 = 87%, Z = 0.63, P = 0.53) (Figure S3). The high heterogeneity may be attributed to differences in breast pump usage: Estafanous [27] employed bilateral electric breast pumps, whereas the other study [26] used manual expression. Due to the limited number of studies, sensitivity analysis could not be performed, and the results should be interpreted with caution. Fig. 4Forest plot of infant formula in hospital Forest plot of infant formula in hospital Infant feeding status at 1–2 weeks postpartum Three studies [26, 28, 33] discussed the Infant feeding status at 1–2 weeks postpartum. We conducted a meta-analysis, which revealed that ABME was significantly associated with exclusive breastfeeding and effectively promoted exclusive breastfeeding (odds ratio [OR]: 2.59; 95% CI: 1.39–4.80, I2 = 0%, Z = 3.01, P = 0.003) (Fig. 5). Based on a pooled control event rate of 32.7%, the absolute risk reduction was 23.0%, resulting in an NNT of 5 (95% CI: 3–13). However, ABME was not significantly associated with either any breastfeeding (odds ratio [OR]: 0.58; 95% CI: 0.30–1.11, I2 = 0%, Z = 1.63, P = 0.1) (Fig. 5) or formula feeding (odds ratio [OR]: 0.36; 95% CI: 0.09–1.41, Z = 1.47, P = 0.14) (Fig. 5). Fig. 5Forest plot of infant feeding status at 1-2 weeks postpartum Forest plot of infant feeding status at 1-2 weeks postpartum Infant feeding status at 3–4 weeks postpartum Three studies [26, 28, 33] discussed infant feeding status at 3–4 weeks postpartum. We conducted a meta-analysis, which showed that ABME was significantly associated with exclusive breastfeeding(odds ratio [OR]: 2.53; 95% CI: 1.24–5.15, I2 = 29%, Z = 2.55, P = 0.01) (Fig. 6) Based on a pooled control event rate (CER) of 34.5% and an absolute risk reduction (ARR) of 22.6%, the corresponding NNT was 5 (95% CI: 3–20). Conversely, ABME significantly reduced the incidence of partial breastfeeding (odds ratio [OR]: 0.3; 95% CI: 0.15–0.6, I2 = 0%, Z = 3.4, P<0.01) (Fig. 6). With a CER of 54.2% and an ARR of 28.0%, the NNT was 4 (95% CI: 3–8) to prevent one case of non-exclusive breastfeeding. However, no significant association was observed between ABME and formula feeding during the same period (odds ratio [OR]: 1.02; 95% CI: 0.16–6.41, I2 = 47%, Z = 0.02, P = 0.98) (Fig. 6). Fig. 6Forest plot of infant feeding status at 3-4 weeks postpartum Forest plot of infant feeding status at 3-4 weeks postpartum Maternal outcomes Spontaneous vaginal In the case of spontaneous vaginal delivery, three studies [26, 27, 33] referred to this outcome indicator. The meta-analyses showed that ABME was not statistically significantly associated with spontaneous vaginal delivery (odds ratio [OR]: 0.76; 95% CI: 0.32–1.82, I2 = 50%, Z = 0.61, P = 0.54) (Fig. S4). Due to moderate heterogeneity, a leave-one-out sensitivity analysis was conducted, which identified the study by Estafanous et al. [26] as the main source of heterogeneity.Exclusion of this study resulted in a substantial reduction in heterogeneity (I² decreased from 50% to 0%) without materially altering the pooled effect size (odds ratio [OR]: 0.44; 95% CI: 0.17–1.11, I2 = 0%, Z = 1.74, P = 0.08) (Fig. S4). Although the P-value approached significance, the association remained statistically non-significant at the conventional threshold. The heterogeneity observed in the primary analysis may be attributable to differences in intervention methods: Estafanous et al. [26] used bilateral electric breast pumps, whereas the other studies [25, 35] employed manual expression. This methodological variation might have influenced the physiological stimulation intensity and subsequent outcomes. Given the limited number of studies and the borderline P-value, further high-quality research with larger sample sizes is warranted to clarify this association. Cesarean section Four studies [26, 27, 29, 33] reported this outcome. Our meta-analysis revealed no significant association between ABME and the likelihood of maternal choice for cesarean delivery (odds ratio [OR]: 1.04; 95% CI: 0.60–1.78, I2 = 0%, Z = 0.13, P = 0.90) (Fig. S6). Blood loss Only one studies [27] mentioned the outcome of blood loss after labor. The mean blood loss was 484 mL (range 30–2000; SD 370.8) in the ABME group and 457 mL (range 25–2300; SD 405.7) in the control group, with no statistically significant difference between groups (P = 0.659). Therefore, meta-analysis was not performed for this outcome due to insufficient data. Neonatal outcomes NICU admission Two studies [26, 27] reported NICU admission. Pooled analysis showed that ABME was not significantly associated with NICU admission (odds ratio [OR]: 1.16; 95% CI: 0.59–2.31, I2 = 0%, Z = 0.43, P = 0.66) (Fig. S7). Apgar score at 5 min Only one study [27] reported the incidence of a 5-minute Apgar score < 6. Three neonates (5%) in the ABME group and three (3%) in the control group had a 5-minute Apgar score < 6, with no statistically significant difference between groups (P = 0.46). Therefore, meta-analysis was not performed for this outcome due to insufficient data. Effects of ABME in Women with Pre-existing or gestational diabetes Three studies [18, 34, 35] originated from the same randomized controlled trial (the DAME trial) conducted in women with pre-existing or gestational diabetes during pregnancy. As these reports were derived from an identical study population but focused on different outcomes and follow-up periods, they were not included in the quantitative synthesis to avoid double-counting of participants. Instead, the findings were narratively summarized. Breastfeeding outcomes Delayed onset of lactogenesis Ⅱ The DAME trial investigated the impact of ABME on the onset of Lactogenesis II among women with diabetes (Type 1, Type 2, or gestational diabetes).The incidence of delayed DOL II (defined as ≥ 72 h postpartum) was 55.8% in the ABME group compared to 58.6% in the standard care group. No significant difference was observed between the two groups (adjusted difference: 4.0%; 95% CI: -4.5% to 12.5%; P = 0.35), suggesting that ABME does not significantly accelerate the physiological onset of milk “coming in” for this population. Breastmilk feeding exclusively for first 24 h ABME showed a significant early clinical benefit. The rate of exclusive breastmilk feeding within the first 24 h was significantly higher in the ABME group than in the control group (69% vs. 60%; adjusted relative risk (aRR) 1.15; 95% CI: 1.02–1.28). Infant feeding status in hospital Patients in the ABME group were more likely to maintain exclusive breastfeeding throughout their hospital stay (57% vs. 49%; aRR, 1.16; 95% CI: 0.99–1.33). Infant feeding status from 1 week to 3 months postpartum postpartum At 1–2 weeks, feeding patterns remained comparable between groups. By 3 months (12–13 weeks), there were no significant differences in the rates of exclusive breastfeeding (aRR 1.07; 95% CI: 0.92–1.22) or any breastfeeding (aRR 0.99; 95% CI: 0.92–1.06) between the intervention and control groups. Maternal outcomes No significant differences were reported in the rates of spontaneous vaginal delivery or cesarean section. Similarly, maternal blood loss was comparable between groups, reinforcing the safety profile of ABME in late pregnancy. Neonatal outcomes NICU Admission The proportion of infants admitted to the NICU was 15% in the ABME group and 14% in the standard care group (aRR, 1.06; 95% CI: 0.66–1.46). Apgar scores There was no evidence that ABME adversely affected neonatal transition, with 5-minute Apgar scores showing no significant intergroup variance. Publication bias A Begg’s test was performed to estimate publication bias based on the primary outcome of the association between ABME and DOL II, and the results showed that no significant publication bias was found (P = 0.452). Discussion Principal findings This study aimed to investigate the effect of ABME on maternal and infant outcomes. Our main findings were as follows:(1) Breastfeeding outcomes: For low-risk pregnancies, the meta-analysis indicated that ABME significantly reduced the risk of DOL II and promoted exclusive breastfeeding at 1–2 and 3–4 weeks postpartum. Conversely, based on a descriptive synthesis of limited evidence for diabetic pregnancies, ABME's benefits were primarily concentrated in the early postpartum period (first 24 hours), with no significant sustained effects on milk onset or long-term feeding status.(2) Maternal outcomes: Maternal safety was consistent across both populations. ABME did not increase the risk of cesarean section, spontaneous vaginal delivery, or postpartum hemorrhage, regardless of the mother's glycemic status.(3) Neonatal Outcomes: Similarly, neonatal outcomes, including NICU admission rates and Apgar scores, remained comparable between the ABME and control groups in both low-risk and diabetic cohorts, confirming the neonatal safety of the intervention. (1) Breastfeeding outcomes: For low-risk pregnancies, the meta-analysis indicated that ABME significantly reduced the risk of DOL II and promoted exclusive breastfeeding at 1–2 and 3–4 weeks postpartum. Conversely, based on a descriptive synthesis of limited evidence for diabetic pregnancies, ABME's benefits were primarily concentrated in the early postpartum period (first 24 hours), with no significant sustained effects on milk onset or long-term feeding status. (1) Breastfeeding outcomes: For low-risk pregnancies, the meta-analysis indicated that ABME significantly reduced the risk of DOL II and promoted exclusive breastfeeding at 1–2 and 3–4 weeks postpartum. Conversely, based on a descriptive synthesis of limited evidence for diabetic pregnancies, ABME's benefits were primarily concentrated in the early postpartum period (first 24 hours), with no significant sustained effects on milk onset or long-term feeding status. (2) Maternal outcomes: Maternal safety was consistent across both populations. ABME did not increase the risk of cesarean section, spontaneous vaginal delivery, or postpartum hemorrhage, regardless of the mother's glycemic status. (2) Maternal outcomes: Maternal safety was consistent across both populations. ABME did not increase the risk of cesarean section, spontaneous vaginal delivery, or postpartum hemorrhage, regardless of the mother's glycemic status. (3) Neonatal Outcomes: Similarly, neonatal outcomes, including NICU admission rates and Apgar scores, remained comparable between the ABME and control groups in both low-risk and diabetic cohorts, confirming the neonatal safety of the intervention. (3) Neonatal Outcomes: Similarly, neonatal outcomes, including NICU admission rates and Apgar scores, remained comparable between the ABME and control groups in both low-risk and diabetic cohorts, confirming the neonatal safety of the intervention. Results of the study in the context of existing literature Our meta-analysis of randomized controlled studies revealed a statistically significant reduction in the risk of DOL II in the ABME group compared to the control group, aligning with findings from several key trials [29, 30]. These results further indicate that ABME significantly promotes exclusive breastfeeding within the first 24 h postpartum, likely due to the immediate availability of stored colostrum. This practice serves as a critical clinical intervention to reduce the need for formula supplementation during the early lactation phase. However, our meta-analysis did not find a significant reduction in the overall use of formula throughout the entire hospitalization period. This finding stands in contrast to the conclusions of Juntereal’s study [36], which suggested a potential for ABME to decrease early hospital formula use. This discrepancy may be attributed to the relatively limited volumes of colostrum typically stored before birth, which, while sufficient for the immediate 24-hour postpartum period, may not be adequate to meet the infant’s nutritional requirements across the entire duration of the hospital stay. Furthermore, the impact of ABME on long-term breastfeeding outcomes may be population-dependent. For low-risk pregnancies, our meta-analysis demonstrated sustained benefits at 1–2 and 3–4 weeks postpartum. In contrast, preliminary evidence from the diabetic subgroup (primarily derived from the DAME trial [34]) suggested that breastfeeding outcomes at three months were comparable to standard care. This implies that while ABME provides a crucial “safety net” in the immediate postpartum period for diabetic cohorts, its long-term efficacy requires further validation. This discrepancy in long-term outcomes may be linked to specific participant characteristics and the distinction between clinical efficacy and real-world effectiveness. As summarized in Table 1, while some trials included both primigravida and multigravida women, the majority of the synthesized evidence originates from primigravida participants, who are clinically more susceptible to DOL II. However, a notable limitation of the included RCTs is the potential self-selection bias during recruitment; women who volunteer for such interventions often possess higher-than-average breastfeeding motivation, which may lead to an overestimation of the intervention’s impact compared to a broader, unselected population. Beyond parity and motivation, the quality of prenatal support plays a pivotal role. A recent systematic review by Sobik et al. [19] highlighted that maternal breastfeeding self-efficacy and experiences are significantly influenced by the quality of education and clinical guidance. This suggests that for women with pregnancy complications, the lack of sustained long-term benefits might not solely stem from physiological limitations, but also from fragmented clinical support and a lack of standardized protocols. Therefore, as various factors—such as unique physical challenges, parity-related lactation history, or concerns about milk supply—influence the decision to continue breastfeeding, future interventions should integrate both technical skill training and robust psychological support to improve long-term outcomes across diverse populations. Regarding safety, ABME demonstrated a reassuring profile with no evidence of adverse obstetric or neonatal effects. Data from randomized controlled trials [18, 27] and cohort studies [15] confirmed no significant differences in gestational age at delivery, postpartum hemorrhage, or delivery mode between groups. Similarly, neonatal outcomes, including NICU admission rates and Apgar scores, remained comparable. While recent research [37, 38] increasingly focuses on the benefits of ABME for managing neonatal hypoglycemia in gestational diabetes, our study highlights that the intervention is safe across both low-risk and diabetic populations. We anticipate that future multi-center trials will further clarify the efficacy of ABME specifically within the diabetic subgroup to strengthen the existing evidence base. Strengths and limitations The strengths of this review include a comprehensive search across ten databases without restrictions on date or language, and the inclusion of only RCTs, which are considered high-quality studies. To our knowledge, this is the first systematic review and meta-analysis to quantitatively synthesize evidence on the impact of ABME on both maternal and infant outcomes. Previous studies primarily consisted of literature reviews with limited scope, lacking thorough data analysis and synthesis. Additionally, our meta-analysis incorporated methodological flaws as part of the inclusion criteria, addressing a common source of bias in related studies. Finally, this study provides valuable insights into essential clinical practices regarding ABME. However, this review has some limitations. We anticipated conducting subgroup analyses on populations with various pregnancy complications, but this was unfeasible due to the limited types of articles and populations included; only one study focused on women with gestational diabetes mellitus. Secondly, the optimal timing for initiating milk expression remains inconclusive, as the protocols in the included studies varied, with initiation ranging from as early as 34 weeks to the more common 36 or 37 weeks of gestation. This variation in the duration of antenatal expression may influence the cumulative volume of colostrum stored and the subsequent breastfeeding outcomes. Additionally, when assessing the occurrence of DOL II, the majority of studies did not explicitly report the exact timing of lactogenesis II onset in postpartum women, thereby limiting a more in-depth analysis of delayed lactogenesis. Furthermore, certain outcomes were evaluated in only one or two studies, restricting the potential for comprehensive data synthesis. Conclusion Although this review included a limited number of studies, primarily involving low-risk singleton pregnancies, the synthesized evidence suggests that ABME is a promising intervention to reduce the incidence of DOL II and enhance exclusive breastfeeding rates through the first month postpartum. However, evidence regarding high-risk populations, particularly those with diabetes, remains preliminary as it is currently derived from a single high-quality trial. Future research should expand their focus to include maternal populations with varying backgrounds of pregnancy complications and incorporate qualitative research to gain deeper insights into maternal perceptions of ABME and their subjective experiences. Additionally, the long-term effects of ABME on breastfeeding outcomes remain to be fully elucidated, highlighting an important direction for further exploration. Furthermore, well-designed randomized controlled trials are still needed to analyze the frequency of ABME, the amount of breast milk stored before delivery, and the impact of ABME on the timing of lactation initiation. This will provide a stronger foundation for future analyses and the development of more effective breastfeeding support strategies. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2. Supplementary Material 3. Supplementary Material 3. Supplementary Material 4. Supplementary Material 4. Supplementary Material 5. Supplementary Material 5. Supplementary Material 6. Supplementary Material 6. Supplementary Material 7. Supplementary Material 7.